Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CSL Ltd. (OTC: CSLLY).

Full DD Report for CSLLY

You must become a subscriber to view this report.

Recent News from (OTC: CSLLY)

CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal
KING OF PRUSSIA, Pa. , Dec. 6, 2018 /PRNewswire/ -- Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal's Most Admired CEOs for 2018, recognizing his patient-focused leadership of the world's fifth largest biotechnology company. ...
Source: PR Newswire
Date: December, 06 2018 09:10
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
HOLLY SPRINGS, N.C. , Nov. 16, 2018 /PRNewswire/ -- Seqirus, a wholly owned subsidiary of CSL Limited and a global leader in influenza prevention, today announced a $140M expansion of its Holly Springs manufacturing facility in North Carolina . The Holly Springs facility is at the ...
Source: PR Newswire
Date: November, 16 2018 09:00
Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options
SUMMIT, N.J. , Nov. 16, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard egg-based quadrivalent vaccin...
Source: PR Newswire
Date: November, 16 2018 08:00
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
SUMMIT, N.J. , Oct. 23, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced the U.S. Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in people six months of age and older, 1 extending the company's ...
Source: PR Newswire
Date: October, 23 2018 08:01
Seqirus Cell-based Influenza Vaccine Nears European Approval
MAIDENHEAD, England , October 19, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced that its cell-based quadrivalent influenza vaccine (QIVc) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the Europe...
Source: PR Newswire
Date: October, 19 2018 08:23
Catalyst Biosciences: Rare Risk/Reward Opportunity
General Overview of Pipeline Catalyst Biosciences ( CBIO ) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates ...
Source: SeekingAlpha
Date: October, 14 2018 22:32
Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
SAN FRANCISCO , Oct. 3, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced data, to be presented at IDWeek 2018 on Saturday, October 6 , showing that higher levels of mismatch have consistently occurred with egg-derived influenza vaccine viruses compar...
Source: PR Newswire
Date: October, 03 2018 17:02
Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek
SAN FRANCISCO , Oct. 3, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, will present new healthcare and cost outcomes data for its MF59®-adjuvanted trivalent influenza vaccine (FLUAD) at IDWeek in San Francisco ( October 5-6 ). Results from five differen...
Source: PR Newswire
Date: October, 03 2018 16:45
CSL Named One of the Top Companies in the World for Diversity and Inclusion
KING OF PRUSSIA, Pa. , Sept. 18, 2018 /PRNewswire/ -- Thomson Reuters has ranked global biotechnology leader CSL Limited one of the top 100 companies in its 2018 global Diversity and Inclusion Index. This achievement reflects CSL's promise to build a workplace culture where employees ha...
Source: PR Newswire
Date: September, 18 2018 09:45
Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process
CAMBRIDGE, Mass. , Aug. 23, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza vaccine innovation, today announced FDA approval of its next generation cell-based manufacturing process at Holly Springs, North Carolina.  The approval will enable Seqirus to more than double curr...
Source: PR Newswire
Date: August, 23 2018 09:23


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CSLLY.

About CSL Ltd. (OTC: CSLLY)

Logo for CSL Ltd. (OTC: CSLLY)

CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent serious and rare medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself. Innovation is at the heart of everything we do. It is reflected in our creation of state of the art plasma collection and manufacturing facilities, our investment in improving current therapies, finding new indications for existing therapies, and innovating new therapeutic products for unmet needs


Contact Information



Current Management

  • Paul Perreault / CEO, Managing Director
  • Paul Perreault / President, CEO
  • Mark Dehring / Director, Inv. Rel.
  • John Shine / Chairman

Current Share Structure

  • Market Cap: $3,080,522,556 - 03/09/2018
  • Authorized: 500,000,000 - 09/01/2015
  • Issue and Outstanding: 23,725,528 - 09/01/2015


Daily Technical Chart for (OTC: CSLLY)

Daily Technical Chart for (OTC: CSLLY)

Stay tuned for daily updates and more on (OTC: CSLLY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CSLLY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CSLLY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CSLLY and does not buy, sell, or trade any shares of CSLLY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: